Anticipate generic drug launch
Manage your formulary budget
Find generic entry opportunities
Drug patents …
… from Kazakhstan to Kalamazoo
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Proactively manage your pharmacy inventory
|Title:||Cerebral therapeutic agent and its use|
|Abstract:||The invention provides pharmaceutical compositions and medicaments, useful for the treatment of cerebral disorders, wherein the active compound is 1,4-dihydro-2,6-dimethyl-4-(3'-nitrophenyl)-pyridine-3-(.beta.-methoxyethy l ester)-5-(isopropyl ester). Also included in the invention are methods for the use of said compositions and medicaments.|
|Inventor(s):||Meyer; Horst (Wuppertal, DE), Bossert; Friedrich (Wuppertal, DE), Kazda; Stanislav (Wuppertal, DE), Hoffmeister; Friedrich (Wuppertal, DE), Vater; Wulf (Leverkusen, DE)|
|Assignee:||Bayer Aktiengesellschaft (Leverkusen, DE)|
1. A method of combating pathologically reduced cerebral functions and performance weaknesses, cerebral insufficiency and disorders in cerebral circulation and metabolism in
warm-blooded animals which comprises administering to the said animals a cerebral specific effective amount for treating said conditions of 1,4dihydro-2,6dimethyl-4-(3'-nitrophenyl)-pyridino-3-(.beta.-methoxyethyl ester)-5-isopropyl ester either alone or
in admixture with a diluent or in the form of a medicament.
2. A method according to claim 1 in which the active compound is administered intravenously in an amount of 0.0001 to 0.5 mg per kg body weight per day, or enterally in an amount of 0.001 to 1 mg per kg body weight per day.
3. A method according to claim 1, in which the compound is administered intravenously in an amount of 0.001 to 0.1 mg per kg body weight per day, or enterally in an amount of 0.01 to 0.5 mg per kg body weight per day.
4. A method according to claim 1 or 2 in which the active compound is administered orally.